1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis

PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis

Summary

GlobalData’s "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, GlobalData provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies.

Highlights

Key Questions Answered

- What are the drivers of the gene therapy field?
- Who are the leading companies involved in the development of gene therapies?
- What are the major trends in gene therapy clinical trials?
- What specific therapeutic areas and indications are receiving the most clinical research?
- What progress has been made in terms of viral vector technology and gene delivery?
- What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?
- Has investor confidence been restored in the gene therapy field?

Scope

- This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments
- Investment examined on both the industry and financial communities
- Broad discussion on the science behind gene therapies, viral vectors, and gene delivery
- Clinical trials activity examined across phase of development, therapy area, and indication.
- This report offers a deep dive into the synergies behind partnering and acquisition activity
- Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action
- Pipeline profiles of 20 leading biotech companies developing gene therapies

Reasons to buy

- Identify the key players in the gene therapy market
- Analyze and track the strategies that companies are using to strengthen their position in the gene therapy field; independent source for due diligence
- Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover
- Understand the flow of investment from capital markets into the gene therapy field

Table Of Contents

PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 12
2.1 Report Scope 12
2.2 Companies Mentioned 13
2.3 Upcoming Reports 13
2.4 Recently Published Reports 13
3 Gene Therapy Overview 14
3.1 What is Gene Therapy? 14
3.2 Gene Delivery 16
3.2.1 Viral Vectors 17
3.2.2 Non-Viral Vectors and Naked DNA 21
4 Market Developments 22
4.1 Turning Point: Glybera Approval 23
4.2 GSK Files Application to the EMA for Gene Therapy for ADA-SCID 24
4.3 Celladon's Reports Negative Results for Mydicar in Advanced Heart Failure 25
4.4 Spark Initiates Phase I/II Clinical Trial of SPK-CHM for Choroideremia 26
4.5 FDA Accepts Sangamo's IND to Begin Trial of Gene Therapy for Beta-Thalassemia 26
4.6 Paying for Gene Therapies: Annuity Model 27
5 Clinical Trials 29
5.1 Overview 29
5.2 Company 31
5.3 Phase of Development 32
5.4 Therapy Area 33
5.5 Indication 35
5.6 Investigators 36
5.6.1 Specialty 36
5.6.2 Country 38
6 Company Analysis 39
6.1 Overview 39
6.1.1 Entity Type 39
6.1.2 Regional Split 39
6.2 Financial Highlights 40
6.2.1 Revenue 41
6.2.2 RandD Spending 42
6.2.3 Market Capitalization 43
6.2.4 Stock Performance 45
6.3 Pipeline Profiles 46
6.3.1 Advantagene 47
6.3.2 ALS Therapy Development Institute 48
6.3.3 Amarna Therapeutics 49
6.3.4 American Gene Technologies International 50
6.3.5 AnGes MG 51
6.3.6 Applied Genetic Technologies Corporation 54
6.3.7 Asklepios BioPharmaceutical 55
6.3.8 Avalanche Biotechnologies 56
6.3.9 Bluebird bio 58
6.3.10 Celladon 60
6.3.11 Dimension Therapeutics 61
6.3.12 GeneCure Biotechnologies 62
6.3.13 Genethon 63
6.3.14 GenSight Biologics 63
6.3.15 Oxford BioMedica 64
6.3.16 ReGenX Biosciences 66
6.3.17 Sangamo BioSciences 67
6.3.18 Spark Therapeutics 70
6.3.19 UniQure 71
6.3.20 Voyager Therapeutics 74
7 Deals Landscape 75
7.1 Overview 75
7.1.1 Geography 77
7.1.2 Entity Type 79
7.1.3 Company 80
7.1.4 Stage 81
7.1.5 Therapy Area 82
7.1.6 Indication 84
7.1.7 Mechanism of Action 86
7.2 Deal Type 86
7.2.1 Mergers and Acquisitions 87
7.2.2 Licensing and Partnerships 89
7.2.3 Capital Raisings 92
8 Strategic Outlook 95
9 Appendix 96
9.1 Bibliography 96
9.2 Research Methodology 96
9.2.1 Coverage 96
9.2.2 Secondary Research 97
9.3 About the Author 98
9.3.1 Adam Dion, Senior Industry Analyst 98
9.4 Global Head of Healthcare 99
9.5 About the Industry Dynamics Team 99
9.6 About GlobalData 100
9.7 Disclosure Information 100
9.8 Disclaimer 100

1.1 List of Tables
Table 1: Common Diseases for Gene Therapy, Defects and Target Cells 15
Table 2: Main Groups of Viral Vectors and Their Characteristics 19
Table 3: Advantagene 48
Table 4: ALS Therapy Development Institute 49
Table 5: Amarna Therapeutics 50
Table 6: American Gene Technologies International 51
Table 7: AnGes MG 53
Table 8: Applied Genetic Technologies Corporation 55
Table 9: Asklepios BioPharmaceutical 56
Table 10: Avalanche Biotechnologies 57
Table 11: Bluebird bio 59
Table 12: Celladon 61
Table 13: Dimension Therapeutics 62
Table 14: GeneCure Biotechnologies 62
Table 15: Genethon 63
Table 16: GenSight Biologics 64
Table 17: Oxford BioMedica 65
Table 18: ReGenX Biosciences 66
Table 19: Sangamo BioSciences 69
Table 20: Spark Therapeutics 71
Table 21: UniQure 73
Table 22: Voyager Therapeutics 74
Table 23: Gene Therapy, MandA Deals Table Summary, 2010-2014 88
Table 24: Gene Therapy, Licensing Deals Table Summary, 2009-2015 90
Table 25: Gene Therapy, Capital Raisings Table Summary, 2013-2015 94

1.2 List of Figures
Figure 1: Number of Gene Therapy Clinical Trials, 2009-2014 29
Figure 2: Number of Gene Therapy Clinical Trials by Indication and Stage 31
Figure 3: Gene Therapy Clinical Trials by Company 32
Figure 4: Gene Therapy Clinical Trials by Phase of Development 33
Figure 5: Gene Therapy Clinical Trials by Therapy Area 34
Figure 6: Gene Therapy Clinical Trials, Percentage by Therapy Area 35
Figure 7: Gene Therapy Clinical Trials, Top Indications 36
Figure 8: Investigators by Specialty, Gene Therapy 37
Figure 9: Investigators by Country, Gene Therapy 38
Figure 10: Gene Therapy Companies, Entity Type 39
Figure 11: Gene Therapy Companies, Regional Split 40
Figure 12: Gene Therapy Companies by Revenue ($m), 2013 42
Figure 13: Gene Therapy Companies by RandD Spending ($m), 2013 43
Figure 14: Gene Therapy Companies by Market Capitalization ($m) 44
Figure 15: Leading Gene Therapy Companies, Stock Performance ($USD) 46
Figure 16: Gene Therapy Deals, Total Number of Deals and Deal Values ($m), 2009-2015 76
Figure 17: Gene Therapy Deals, Deal Value ($m) by DealType, 2014 77
Figure 18: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Region, 2009-2015 78
Figure 19: Gene Therapy Deals by Region, 2009-2015 78
Figure 20: Gene Therapy Deals by Region, Deal Value ($m), 2009-2015 79
Figure 21: Gene Therapy Deals by Entity Type, Private vs. Public, 2009-2015 79
Figure 22: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Company, 2009-2015 80
Figure 23: Gene Therapy Deals, Number of Deals and Deal Values ($m), by Product Stage, 2009-2015 82
Figure 24: Gene Therapy Deals, Number of Deals and Deal Values ($m), by Therapy Area, 2009-2015 83
Figure 25: Gene Therapy Deals by Indication, (>$500m), 2009-2015 84
Figure 26: Gene Therapy Deals by Indication, (Figure 27: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Mechanism of Action, 2009-2015 86
Figure 28: Gene Therapy Deals, Number of MandA Deals and Deal Values ($m), 2010-2015 87
Figure 29: Gene Therapy, Number of Licensing Deals and Deal Values ($m), 2009-2015 89
Figure 30: Gene Therapy, Number of Capital Raisings and Deal Values ($m), 2009-2015 92
Figure 31: Gene Therapy, Number of Capital Raisings by Financial Advisor, 2009-2015 93

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

Regenerative Medicine Market: By Therapy (Cell Therapy, Gene Therapy, Others), By Product (Autologous Cell-Based, Allogeneic Cell-Based, Acellular), By Application (Orthopaedic & Musculoskeletal Spine, Dermatology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Regenerative medicines are capable of restoring the functionality of cells & tissues by treating a patient with laboratory grown cells and tissues. Regenerative medicines are used in a wide range of degenerative ...

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

  • $ 2995
  • Industry report
  • October 2016
  • by Currentpartnering

The Global Gene Therapy Partnering Agreements 2010-2016 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. ...

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026

  • $ 2349
  • Industry report
  • October 2016
  • by Roots Analysis Private Ltd.

INTRODUCTION Gene therapy has emerged as a promising treatment option for various diseases (primarily the ones that currently have no cure) including cancers, inherited disorders and some viral infections. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.